Skip to main content

Table 3 Medical cost estimation

From: Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database

(Unit: USD)

Ā Ā Ā 
Ā 

GEM-E

GEM

p-valuea

Ā 

(nā€‰=ā€‰1,331)

(nā€‰=ā€‰2,936)

Ā 

Inpatient cost (Meanā€‰Ā±ā€‰SD)b

14,846.70ā€‰Ā±ā€‰11,865.27

13,211.07ā€‰Ā±ā€‰1,0931.57

<0.0001

Length of stay (Meanā€‰Ā±ā€‰SD)

64ā€‰Ā±ā€‰53

63ā€‰Ā±ā€‰54

0.8032

Outpatient cost (Meanā€‰Ā±ā€‰SD)b

6,152.29ā€‰Ā±ā€‰7,233.05

6,066.95ā€‰Ā±ā€‰7,001.03

0.6920

Medication cost (Meanā€‰Ā±ā€‰SD)b

3,264.00ā€‰Ā±ā€‰4,579.44

1,169.20ā€‰Ā±ā€‰1,644.40

<0.0001

Total medical costs (Meanā€‰Ā±ā€‰SD)b

23,819.51ā€‰Ā±ā€‰15,106.18

19,927.98ā€‰Ā±ā€‰14,444.86

<0.0001

  1. Abbreviation: GEM Gemcitabine, GEM-E Gemcitabineā€‰+ā€‰Erlotinib
  2. aDifferences between GEM and GEM-E was tested with t-test after log transformation
  3. bAverage 2013 exchange rate: one US dollar (USD)ā€‰=ā€‰1,113.85 Korea Won (KRW)